Psychotropic drug use with successful and unsuccessful community placed developmentally disabled groups.

Paul et al. (1987) looked at medication lists for adults with developmental disabilities.

They compared two groups: people who stayed in community homes and people who moved back to institutions.

The goal was to see if drug patterns could predict which placements would last.

The paper only describes the numbers; it does not say which group did better.

Still, it was the first hint that medication records might flag future placement failure.

Branford (1997) extends this idea. After large hospitals closed, most people kept the same drugs in group homes. Drug load did not drop just because the setting changed.

Cerutti et al. (2004) zoom in further. They tracked 2 344 adults for 17 months and saw poly-pharmacy rise, especially with new antipsychotics like risperidone.

Fahmie et al. (2013) supersedes the 1987 snapshot. Their survey of 4 000 New York adults shows 58 % on psychotropics, but half of those prescriptions now list a psychiatric diagnosis, not just “behavior control.” The field has shifted toward medical justification.

You can treat each medication review as an early-warning system. If a new client carries three or more psychoactive drugs and no clear diagnosis, pause the placement clock. Ask the doctor why each drug is there, request behavior data, and line up a taper plan before move-in. This simple step can prevent the “med-first” failures that R et al. first spotted almost forty years ago.